Use of rituximab in systemic lupus erythematosus in children: a review
https://doi.org/10.14412/1995-4484-2019-578-583
Abstract
Juvenile-onset systemic lupus erythematosus (SLE) is a significant and urgent problem in the practice of pediatricians and rheumatologists in both verifying its diagnosis and choosing treatment policies, by taking into account the features of the onset, the types of the disease course, and the high probability of an unfavorable prognosis. Despite the tremendous progress made in rheumatology at the beginning of the 21st century, the results of SLE therapy in children and adolescents cannot be considered to be satisfactory: only 13% of patients who fell ill in childhood have drug-free remission in adulthood with a lower quality of life and a higher index of damage. The purpose of this review is to analyze the efficacy and safety of rituximab that, despite the absence of its officially recorded indications, has relatively widely entered the actual clinical practice of pediatric rheumatologists as the drug of choice in the highly active, prognostically unfavorable course of SLE.
About the Author
A. N. Arefyeva
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
Alia Arefyeva.
34A, Kashirskoe Shosse, Moscow 115522.
References
1. Hoffman IE, Lauwerys BR, De Keyser F, et al. Juvenile-onset systemic lupus erythematosus: different clinical and serological pattern than adult-onset systemic lupus erythematosus. Ann Rheum Dis. 2009 Mar;68(3):412-5. doi: 10.1136/ard.2008.094813. Epub 2008 Oct 17.
2. Tucker LB, Uribe AG, Fernandez M, et al. Adolescent onset of lupus results in more aggressive disease and worse outcomes: results of a nested matched case-control study within LUMINA, a multiethnic US cohort (LUMINA LVII). Lupus. 2008;17(4):314-22. doi: 10.1177/0961203307087875
3. Brunner HI, Gladman DD, Ibanez D, et al. Difference in disease features between childhood-onset and adult-onset systemic lupus erythematosus. Arthritis Rheum. 2008;58(2):556-62. doi: 10.1002/art.23204
4. Chatham WW, Kimberly RP. Treatment of lupus with corticosteroids. Lupus. 2001;10(3):140-7. doi: 10.1191/09612030167507500
5. Katsifis GE, Tzioufas AG. Ovarian failure in systemic lupus erythematosus patients treated with pulsed intravenous cyclophosphamide. Lupus. 2004;13(9):673-8. doi: 10.1191/0961203304lu2012oa
6. Feng L, Deng J, Huo DM, et al. Mycophenolate mofetil versus azathioprine as maintenance therapy for lupus nephritis: a metaanalysis. Nephrology (Carlton). 2013;18(2):104-10. doi: 10.1111/nep.12006
7. Baranov AA, Namazova-Baranova LS, Alekseeva EI, Valieva SI, Bzarova TM, Nikishina IP. Clinical recommendations: juvenile arthritis. 2017. ID: КР477. Available from: http://www.pediatr-russia.ru/sites/default/files/file/kr_yua.pdf (In Russ.)
8. Baranov AA, Namazova-Baranova LS, Alekseeva EI, Valieva SI, Bzarova TM, Nikishina IP, Kashchenko EM. Clinical recommendations: Juvenile arthritis with systemic onset. 2017. ID: KR26. Available from: http://www.pediatr-russia.ru/sites/default/files/file/kr_yuassn.pdf (In Russ.).
9. Alekseeva EI, Dvoryakovskaya TM, Nikishina IP, et al. Systemic lupus erythematosus: clinical recommendations. Part 2. Voprosy Sovremennoy Pediatrii. 2018;17(2):110-25 (In Russ.).
10. Shan D, Ledbetter JA, Press OW. Signaling events involved in antiCD20-induced apoptosis of malignant human B cells. Cancer Immunol Immunother. 2000;48(12):673-83. doi: 10.1007/s002620050016
11. Flieger D, Renoth S, Beier I, et al. Mechanism of cytotoxicity induced by chimeric mouse human monoclonal antibody IDECC2B8 in CD20-expressing lymphoma cell lines. Cell Immunol. 2000;204(1):55-63. doi: 10.1006/cimm.2000.1693
12. Alas S, Emmanouilides C, Bonavida B. Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis. Clin Cancer Res. 2001;7(3):709-23.
13. Anolik JH, Campbell D, Felgar RE, et al. The relationship of Fc RIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum. 2003;48(2):455-9. doi: 10.1002/art.10764
14. Boye J, Elter T, Engert A. An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. Ann Oncol. 2003;14(6):520-35. doi: 10.1093/annonc/mdg175
15. Cohen Y, Solal-Celigny P, Polliack A. Rituximab therapy for follicular lymphoma: a comprehensive review of its efficacy as primary treatment for relapsed disease, retreatment and maintenance. Haematologica. 2003;88:811-23.
16. Petschner F, Walker UA, Schmitt-Graff A, et al. «Catastrophic systemic lupus erythematosus» with Rosai-Dorfman sinus histiocytosis. Successful treatment with anti-CD20/rituximab. Deutsch Med Wochenschr. 2001;Sep 14;126(37):998-1001. doi: 10.1055/s-2001-17109
17. Leandro MJ, Edwards JC, Cambridge G, et al. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum. 2002;46:2673-7. doi: 10.1002/art.10541
18. Tew GW, Rabbee N, Brunetta PG, Keir ME. Baseline autoantibody profiles predict normalization of complement and anti-dsDNA autoantibody levels following rituximab treatment in systemic lupus erythematosus. Lupus. 2010 Feb;19(2):146-57. doi: 10.1177/0961203309350752. Epub 2009 Nov 27.
19. Merrill J, Buyon J, Furie R, et al. Assessment of flares in lupus patients enrolled in a phase II/III study of rituximab (EXPLORER). Lupus. 2011 Jun;20(7):709-16. doi: 10.1177/0961203310395802. Epub 2011 Apr 8.
20. Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2010 Jan;62(1):222-33. doi: 10.1002/art.27233
21. Rovin BH, Furie R, Latinis K, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum. 2012 Apr;64(4):1215-26. doi: 10.1002/art.34359. Epub 2012 Jan 9.
22. Hui-Yuen JS, Nguyen SC, Askanase AD. Targeted B-cell therapies in the treatment of adult and pediatric systemic lupus erythematosus. Lupus. 2016;25:1086-96. doi: 10.1177/0961203316652491
23. Cobo-Ibanez T, Loza-Santamaria E, Pego-Reigosa JM, et al. Efficacy and safety of rituximab in the treatment of non-renal systemic lupus erythematosus: a systematic review. Semin Arthritis Rheum. 2014;44:175-85. doi: 10.1016/j.semarthrit.2014.04.002
24. Duxbury B, Combescure C, Chizzolini C. Rituximab in systemic lupus erythematosus; an update systemic review and meta-analysis. Lupus. 2013;22:1489-503. doi: 10.1177/0961203313509295
25. Nasonov EL, editor. Anti-B-kletochnaya terapiya v revmatologii: fokus na rituksimab [Anti-B-cell therapy in rheumatology: focus on rituximab]. Moscow: IMA-PRESS; 2012. 344 p. (In Russ.).
26. Tsanyan ME, Solovyev SK, Nasonov EL, et al. Anti-B cell therapy in patients with systemic lupus erythematosus. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2017;11(4):73-8 (In Russ.). doi: 10/14412/1996-7012-2017-4-73-78
27. Mesnyankina AA, Solovyev SK, Aseeva EA, Nasonov EL. The efficiency of biological therapy and the features of humoral immunity in patients with systemic lupus erythematosus. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(3):302-9 (In Russ.). doi: 10.14412/1995-4484-2018-302-309
28. Groot N, de Graeff N, Avcin T, et al. European evidence-based recommendations for diagnosis and treatment of childhood-onset systemic lupus erythematosus: the SHARE initiative. Ann Rheum Dis. 2017 Nov;76(11):1788-96. doi: 10.1136/annrheumdis-2016-210960. Epub 2017 Jun 19.
29. Jansson AF, Sengler C, Kuemmerle-Deschner J, et al. B-celldepletion for autoimmune disease in pediatric patients. Clin Rheumatol. 2011;30:87-97. doi: 10.1007/s10067-010-1630-0
30. Watson L, Beresford MW, Maynes C, et al. The indications, efficacy and adverse events of rituximab in a large cohort of patients with juvenile-onset SLE. Lupus. 2015;24:10-7. doi: 10.1177/0961203314547793
31. Willems M, Haddad E, Niaudet P, et al. Rituximab therapy for childhood-onset systemic lupus erythematosus. J Pediatr. 2006;148:623-7. doi: 10.1016/j.jpeds.2006.01.041
32. Su GX, Wu FQ, Wang F, et al. Rituximab therapy foe severe pediatric systemic lupus erythematosus. Zhonghua Er Ke Za Zhi. 2012;50:697-704.
33. Lehman TJ, Singh C, Ramanathan A, et al. Prolonged improvement of childhood onset systemic lupus erythematosus following systemic administration of rituximab and cyclophosphamide. Pediatr Rheumatol Online J. 2014;12:3. doi: 10.1186/1546-0096-12-3
34. Alekseeva EI, Denisova RV, Valieva SI, et al. Efficacy and safety of rituximab in children with systemic lupus erythematosus: results of a retrospective study of the case series. Voprosy Sovremennoy Pediatrii. 2016;15(5):497-504 (In Russ.). doi: 10.15690/vsp.v15i5.1624
35. Olfat M, Silverman SD, Levy DM. Rituximab therapy has a rapid and durable response for refractory cytopenia in childhood-onset systemic lupus erythematosus. Lupus. 2015;24:966-72. doi: 10.1177/0961203315578764
36. Tambralli A, Beukelman T, Cron RQ, Stoll ML. Safety and efficacy of rituximab in childhood-onset systemic lupus erythematosus and other rheumatic disease. J Rheumatol. 2015;42:541-6. doi: 10.3899/jrheum.140863
37. Nwobi O, Abitbol CL, Chandar J, et al. Rituximab therapy for juvenile-onset systemic lupus erythematosus. Pediatr Nephrol. 2008;23:413-9. doi: 10.1007/s00467-007-0694-9
38. Podolskaya A, Stadermann M, Pilkington C, et al. B-cell depletion therapy for 19 patients with refractory systemic lupus erythematosus. Arch Dis Child. 2008;93:401-6. doi: 10.1136/adc.2007.126276
39. Ale'ed A, Alsonbul A, Al-Mayouf SM. Safety and efficacy of combined cyclophosphamide and rituximab treatment in recalcitrant childhood lupus. Rheumatol Int. 2014;34:529-33. doi: 10.1007/s00296-013-2896-8
40. Pavon-Sanchez JM, Sanchez-Sanchez LM. Rituximab in pediatric patients with systemic lupus erythematosus. Gac Med Mex. 2013;149:492-6.
41. Sfiakis PP, Boletis JN, Tsokos GC. Rituximab anti-B-cell therapy in systemic lupus erythematosus: pointing to the future. Curr Opin Rheumatol. 2005;17:550-7. doi: 10.1097/01.bor.0000172798.26249.fc
42. Kostik MM, Kuchinskaya EM, Abduragimova FN, et al. Experience with rituximab in children with systemic lupus erythematosus: a retrospective study of a series of cases. Voprosy Sovremennoy Pediatrii. 2016;15(3):295-300 (In Russ.). doi: 10.15690/vsp.v15i3.1567
43. Fornoni A, Sageshima J, Wei C, et al. Rituximab targets podocytes in reccurent focal segmental glomerulosclerosis. Sci TransI Med. 2011;3:85ra46. doi: 10.1126/scitranslmed.3002231
44. Gibson KL, Gipson DS, Massengill SA, et al. Predictors of relapse and end stage kidney disease in proliferative lupus nephritis: focus on children, adolescents, and young adults. Clin J Am Soc Nephrol. 2009;4:1962-7. doi: 10.2215/CJN.00490109
45. Costa-Reis P, Nativ S, Isgro J, et al. Major infections in a cohort of 120 patients with juvenile-onset systemic lupus erythematosus. Clin Immunol. 2013;149(3):442-9. doi: 10.1016/j.clim.2013.08.009
Review
For citations:
Arefyeva A.N. Use of rituximab in systemic lupus erythematosus in children: a review. Rheumatology Science and Practice. 2019;57(5):578-583. (In Russ.) https://doi.org/10.14412/1995-4484-2019-578-583
Views:
1072
Email this article 